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Our perception of preleukaemia as a clinical syndrome has
changed during the last 5-10 years. Block et al. (1953)
observed that it was sometimes difficult to determine the
exact time at which a particular patient with refractory
anaemia might be classified as leukaemic and that in any
case the diagnosis of preleukaemia could only be
substantiated finally by the terminal appearance of overt
clinical leukaemia. More recently, the preleukaemic states
have been defined more precisely and the French-American-
British (FAB) group have proposed that all these conditions
are grouped together as the myclodysplastic syndromes
(MDS) (Bennett et al., 1982). It is now generally accepted
that this represents clonal abnormalities of haemopoietic
stem cells characterised by a variety of phenotypic
manifestations and with a high risk of eventual leukaemic
transformation (Greenberg, 1983; Jacobs, 1985). The clinical
syndromes of refractory anaemia, with or without sidero-
blasts, and with high or low numbers of blast cells in the
bone marrow, have been fully described in recent reviews
(Francis & Hoffbrand, 1985; Jacobs, 1985).
Increasing clinical awareness has resulted in the diagnosis
of preleukaemic states at an earlier stage in their
development but we still have no clear conception of how
the abnormality arises or progresses to its eventual overtly
malignant termination. In attempting to describe a model for
this process we need to take account of the available clinical
data in this condition, current hypotheses regarding the
mechanism of malignant transformation and the probable
identity of the target cell in the haemopoietic system.
Clinical data
Most patients with MDS are anaemic and a wide range of
morphological, immunological and functional red cell
abnormalities have been described (Jacobs, 1985). There may
be a variety of metabolic abnormalities (Valentine et al.,
1973; Cetto et al., 1982), the reappearance of haemoglobin F
(Richard et al., 1979), acquired haemoglobin H (Boehme et
al., 1978) and changes in membrane antigens (Levine et al.,
1984). These changes are associated with gross dyserythro-
poietic appearances in the bone marrow with both nuclear
and cytoplasmic abnormalities. There may be erythroid
hyperplasia, and in such cases sideroblastic granules
indicating mitochondrial iron deposition can usually be
found in a varying proportion of erythroblasts.
The peripheral blood granulocyte count is usually normal
or low and there may be a raised monocyte count.
Granulocytes commonly show reduced nuclear segmentation
and reduced or absent granules. Cytochemical abnormalities
include reduced myeloperoxidase (Schofield et al., 1983) and
inappropriately increased o-naphthyl acetate esterase activity
(Scott et al., 1983). Abnormalities of both myeloid and
macrophage lineage-specific surface markers are common
(Clark et al., 1985). Neutrophil function is abnormal in
about half of all cases (Boogaerts et al., 1983).
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Thrombocytopenia is common and the platelets produced
may be abnormal in both morphology (Maldonado & Pierre,
1975) and function (Lintula et al., 1981). Micromega-
karyocytes with poor granule formation are common in the
bone marrow (Bennett et al., 1982). Occasional patients with
sideroblastic anaemia have been reported with an
abnormally high platelet count (May et al., 1985; Carroll et
al., 1986). Amongst 54 sideroblastic patients seen in Cardiff,
5 had a pathologically high platelet count.
Bone marrow morphology is virtually always abnormal in
patients with MDS. Although the combination of hyper-
cellularity with a peripheral blood cytopenia is commonly
seen, the marrow may be hypoplastic (Fohlmeister et al.,
1985a; Frisch & Bartl, 1986). Progression is marked by a
gradual increase in the proportion of blast cells. In the FAB
terminology, less than 5% blast cells is designated refractory
anaemia (RA), 5-20% blast cells refractory anaemia with
excess blasts (RAEB) and 20-30% blasts RAEB in trans-
formation. The one year survival following diagnosis in our
patients is: primary acquired sideroblastic anaemia (PASA)
95%, RA 64% and RAEB 35%. Most of these patients
eventually die from either haemorrhage or sepsis following
suppression of normal haemopoiesis and functional
inadequacy of the abnormal haemopoietic clone. The classic
picture of acute myeloblastic leukaemia only emerges in 17-
40% of patients (Foucar et al., 1985; Todd & Pierre, 1986;
Coiffier et al., 1983; Greenberg, 1983).
Abnormal proliferation of bone marrow cells
Wickramasinghe (1975) showed that an increased number of
polychromatic erythroblasts from patients with PASA were
in G2 and a reduced number in S phase, compared to
normal, a picture similar to that in vitamin B12 deficient
marrow. Many cells are arrested in midcycle or in G2 and
this state is associated with defective protein synthesis and
cell death which is expressed in functional terms as
ineffective erythropoiesis. Mitrou and Fisher (1979) made
similar observations in six patients with non-sideroblastic
refractory anaemia. A parallel study of proliferating myeloid
cells showed similar abnormalities in the group as a whole,
but within the same marrow specimen it was possible for
severe myeloid abnormalities to be accompanied by normal
erythropoiesis. A low labelling index for nucleated red cells
and myeloid cells in patients with myelodysplastic syndrome
has been confirmed by several workers (Hast & Reizenstein,
1977; Seigneurin & Hollard, 1981; Karsdorf et al., 1983).
Those patients with the lowest labelling index, indicating the
greatest impairment of DNA synthesis, have the poorest
prognosis and the highest probability of leukaemic change.
Flow cytometric measurements of DNA in whole marrow
confirms that those myelodysplastic patients with the highest
proportion of cells in S and G2 phases of the cell cycle have
the best prognosis and those with an increased proportion of
cells in GO/G, have the greatest risk of leukaemic change
(Montecucco et al., 1983; Peters et al., 1986).
The evaluation of erythroid production using a
mathematical model for the interpretation of ferrokinetic
data showed that ineffective erythropoiesis was the major
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factor causing anaemia in patients with PASA (Barosi et al.,
1978). In an extension of this work, quantitative data on
total marrow iron turnover, ineffective erythropoiesis, and
red cell lifespan in 43 patients with myelodysplastic
syndrome were studied by cluster analysis (Cazzola et al.,
1982) and the data resolved into three clusters. The poorest
survival was found in the cluster with the lowest erythroid
production, and the best survival in the cluster with
erythroid hyperplasia and a high level of ineffective erythro-
poiesis. More recent studies showed ineffective erythropoiesis
to be an early manifestation of MDS (May et al., 1985) and
erythroid hyperplasia seen in initial marrow aspirates to be
associated with the longest survival (Jacobs & Clark, 1987).
Cytogenetic abnormalities
Karyotypic abnormalities in haemopoietic cells are common,
being found in about 50% of cases by most workers (Sokal
et al., 1980; Jacobs et al., 1986). A higher incidence has been
found in some series (Yunis et al., 1986), possibly due to
differences in patient selection and in laboratory techniques.
Many of the non-random chromosomal aberrations are
similar to those found in some cases of acute myeloblastic
leukaemia (AML), though certain abnormalities typical of
specific subgroups of AML are rarely seen in MDS. These
include the 8:21 translocation often found with acute myelo-
blastic leukaemia of FAB type M2, the 15:17 translocation
often found with acute promyelocytic leukaemia (FAB type
M3), and the 19:22 translocation of chronic granulocytic
leukaemia.
The most common abnormalities are monosomy 5 or 5q-,
monosomy 7 or 7q- and trisomy 8. Many others have been
described. Patients with a normal karyotype usually have a
longer survival (Todd & Pierre, 1986), those with an initial
abnormality at the time of diagnosis tend to have a less
stable karyotype, evolve into a 'more malignant' clinical
group and have a poorer survival. Only a small minority of
patients with erythroid hyperplasia and sideroblastic
precursors have an abnormal keryotype, but those showing
abnormalities usually have a rapid clinical evolution (Yunis
et al., 1986). The presence of monosomy 7 or 7 deletions,
usually of the long arm, is associated with a rapidly
progressive course and a poor survival (Yunis et al., 1986).
Patients with marrow morphology showing myeloid hyper-
plasia and an increased number of blast cells usually have a
high incidence of karyotype abnormalities, often with
multiple complex derangements. They have a very poor
prognosis. Multiple independent clones are commonly found
in the preleukaemic state.
Although some patients with primary MDS have a history
of exposure to chemical agents this does not appear to relate
to a specific clinical picture or chromosome defect. Patients
treated with chemotherapy or radiotherapy have a high
incidence of secondary MDS and AML with a uniformly
poor prognosis. This particularly malignant form of pre-
leukaemia is associated with a clonal abnormality of
chromosomes 5 and 7 in most cases. The critical regions
appear to be 5q23-q32 and 7q32-33 or 7q34-35 (Le Beau et
al., 1986). Chromosomes 1, 4, 12, 14 and 18 appear to be
involved significantly more often in therapy-induced MDS
and AML than in the same conditions occuring de novo (Le
Beau et al., 1986).
DNA content ofbone marrow cells
It is often difficult to evaluate either the frequency or the
extent of cytogenetic aberrations in patients with pre-
leukaemia because chromosome spreads suitable for analysis
may be few in number and poor in quality (Nowell, 1982).
When ploidy is measured in marrow cells by DNA content
with high resolution flow cytometry (Barlogie et al., 1983),
aneuploidy is found in about half the patients (Clark et al.,
1986), those with a low percentage of blasts tending to be
hyperdiploid. A few patients with increased blast cell
numbers show two separate GO/G1 peaks. Sideroblastic
anaemia appears to be associated with hyperdiploidy, while
hypodiploidy was found most commonly in patients with
high numbers of marrow blasts (Clark et al., 1986). Patients
with hypodiploid marrow cells had a significantly shorter
survival time than other patients and hypodiploidy appeared
to be a better indicator of prognosis than the marrow blast
count. These data suggest that there is a relationship
between the loss of chromosomal material and progression
towards a leukaemic phenotype.
Haemopoietic progenitors
Impaired in vitro growth of CFU-GM colonies from marrow
cells has been widely observed (Milner et al., 1977; Green-
berg & Mara, 1979; Verma et al., 1979) and in some cases
growth patterns have been related to prognosis (Verma et
al., 1979; Spitzer et al., 1979). Erythroid colony growth is
usually decreased in preleukaemic marrows (Milner et al.,
1977; Amato & Kahn, 1983; May et al., 1985) but in PASA
patients a combination of impaired or absent erythroid
growth with normal or high CFU-GM growth is common
(Ruutu et al., 1984; May et al., 1985).
Clinical progression
The evolution of one clinical type of MDS into another with
a poorer prognosis and the eventual emergence of AML in a
substantial number of cases is commonly observed.
Fohlmeister et al. (1985b) have suggested, on the basis of
sequential observations in individual patients, that in many
cases an initial marrow hypoplasia is followed by a phase of
erythroid hyperplasia and ineffective erythropoiesis. This, in
turn, is succeeded by a phase of myeloid hyperplasia with
the later emergence of circumscribed nests of blast cells,
suggesting new subclones arising within the pre-existing
dysplastic clone. This scheme is compatible with the
association of sideroblastic change, erythroid hyperplasia and
hyperdiploidy with early stage disease and a relatively good
survival. It must be rare for a patient to proceed from a
'myeloid' to an 'erythroid' phase.
Possible models
The multistage nature of malignant transformation is well
recognised (Knudson, 1973; Land et al., 1983; Klein &
Klein, 1985), though even in a specific tumour type the
nature and sequence of these steps may vary and the
malignant phenotype may be reached by different routes.
The gradual evolution of a haemopoietic stem cell through
the sequential stages from an initial genetic insult, the
development of preleukaemia and progression to leukaemia
is clearly in accordance with this general model (Jacobs,
1985). The initially damaged stem cell may well be undetec-
table by conventional methods of examination and many
such cells, or even minor clonal populations, may fail to
survive either due to a metabolic disadvantage or through
destruction by the host immune defences. A further genetic
change may be necessary before growth control mechanisms
are altered sufficiently to give the new clone a proliferative
advantage over normal haemopoietic cells. Such an
advantage and the consequent clonal expansion may be
related to increased sensitivity to growth factors, autocrine
stimulation or inhibition of normal haemopoiesis. Clinical,
morphological and cytogenetic data suggest that the progress
of preleukaemia is marked by greatly varying rates of clonal
expansion, or by clonal evolution with new populations
having greater malignant potential (Tricot et al., 1985;
Tomonaga et al., 1984). Except in specific instances, such as
post-chemotherapy marrow damage, the nature of the
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can be involved. Similarly we have no clear information
regarding the possibility of inherited genetic lesions pre-
disposing to malignant change (de Vinuesa et al., 1985;
Krontiris et al., 1986).
The genetic lesions giving rise to the preleukaemic process
may be of two types. Firstly, each step may be related to a
specific abnormality resulting in gene activation,
amplification or deletion. At least three relevant groups of
genes have been described, oncogenes (transforming genes),
suppressor genes (anti-oncogenes) (Green & Wyke, 1985)
and modulator genes (Klein & Klein, 1985). The recent burst
of information linking oncogene proteins to specific
functional roles in the regulation of cell proliferation
(Burgess, 1985) and their place in multistep carcinogenesis
has made it attractive to suppose that defects in the function
of these genes play an important, if not an essential, role in
the development of malignancy (Land et al., 1983; Deuel &
Huang, 1984; Klein & Klein, 1985; Bradshaw, 1986). The
evidence in relation to human disease is, however,
circumstantial and some doubts have been expressed as to
whether oncogene abnormalities are sufficient or even
necessary to cause cancer (Duesberg, 1985; Editorial, 1986).
Secondly the evolution of leukaemia is associated with
increasing chromosomal instability characterised grossly by
aneuploidy, translocations, marker chromosomes and, in
some cases, a progressive loss of chromosomal material.
Knuutila et al. (1984) suggest that in MDS chromosome
instability is associated with hypodiploid clones and
aberrations in chromosome 7, and Clark et al. (1986) have
shown that hypodiploidy is associated with poor survival.
Increasing genomic instability appears to be an important
feature in the progression of preleukaemia and may well
provide a mechanism for the emergence of multiple
abnormal clones, usually with chromosome loss. Most of
these will not survive but some will have increased malignant
potential.
Functional abnormalities in MDS
Both leukaemia and myelodysplasia are characterised by
gradual expansion of an undifferentiated self perpetuating
stem cell population with poorly differentiated progeny.
Knowledge of the mechanisms controlling, the balance
between stem cell renewal and maturation is imperfect and it
is still not clear whether differentiation is precisely pro-
grammed at a genetic level or whether it is coupled to
proliferative activity by humoral interactions (Sachs, 1982;
Nicola & Metcalf, 1985).
In clinical terms the earliest manifestations of MDS
commonly include evidence of ineffective erythropoiesis
associated with cell cycle abnormalities and premitotic cell
death. An analogous, though not so well characterised,
process probably occurs in myeloid precursors. At this stage
an accompanying marrow hyperplasia compensates for cell
loss and maintains the supply of end cells to the peripheral
blood, though these may be functionally defective. This
suggests that the normal feedback mechanisms regulating the
flow of mature blood cells from the marrow are still
maintained. At a later stage the production of mature cells
gradually fails, either due to a growth factor/receptor abnor-
mality or to the gradual expansion of the undifferentiated
cell population, seen clinically as an increase in marrow
blast cells.
It is tempting to try and implicate abnormalities of those
genes, such as )nYc, thought to be related to cell cycle
control in the early phase of MDS and to speculate on the
possible role of src in stem cell self renewal (Boettiger &
Dester, 1986) or fos in differentiation (Muller, 1986), but at
present we have no evidence for the involvement of these
oncogenes in the preleukaemic process. It is simplistic to
suggest that only a few specific genes are involved in the
heterogenous picture of myelodysplasia but the accumulating
evidence that chromosomes 5, 7 and 8 are the most common
sites for karyotype abnormalities does draw attention to the
possible role of oncogenes at these locations. In addition to
fins (5q34), coding for the M-CSF receptor (Sherr et al.,
1985), mnyc (8q24), mos (8q22) and met (7q21-q31), the gene
for GM-CSF is located at 5q21-q32 (Huebner et al., 1985),
the A-chain of PDGF is coded on chromosome 7 (Betsholtz
et al., 1986) and M-CSF on chromosome 5 close to GM-
CSF (Rowley, personal communication). However, activated
N-ras has also been identified in human myeloid leukaemia
(Bos et al., 1985; Hirai et al., 1985) and abnormal expression
of other oncogenes has been observed (Blick et al., 1984).
What is the target cell?
Evidence of the underlying clonality of haemopoiesis in
MDS comes from an abundance of karyotype data and a
few well studied cases with G6PD heterozygosity (Jacobs,
1985). There is, however, no clear evidence regarding the
nature of the clonogenic cell. The patient studied by Prchal
et al., (1978) showed the same G6PD isoenzyme in myeloid
and erythroid cells, platelets, macrophages, T and B cells,
suggesting a disordered pluripotential stem cell. In the
patient of Abkowitz et al. (1984) T cells were polyclonal (B
cells were not studied), suggesting either that the clonogenic
cell had restricted lineage potential or that a substantial
number of long-lived normal T cells persisted in the
circulation. Raskind et al. (1984) investigated a patient with
both enzyme and karyotypic evidence of clonality and
showed that although B cell lines produced by Epstein-Barr
virus transformation contained only the single G6PD
isoenzyme found in erythroid and myeloid cells, none of
them contained the clonal karyotype abnormality found in
the marrow. These workers hypothesised that an initial
lesion may be found in the pluripotent stem cells and a
second lesion producing chromosome abnormalities may
occur in one of its progeny.
Similar evidence from the myeloid leukaemias suggests
that the transformed cell may have restricted lineage
potential. Fialkow (1985) found that in 5 elderly women
with acute myeloblastic leukaemia (AML) the leukaemic
stem cell was pluripotential for myeloid, erythroid, mega-
karyocytic and probably B-cell lines. However, in 10 younger
AML patients the abnormal stem cell appeared to be
restricted to the myeloid lineage. Lineage restriction to the
monocytic pathway has also been described (Ferraris et al.,
1984). There are two possible explanations tor lineage
restriction in the abnormal clone. Either the target for the
leukaemogenic insult is already a partially committed cell or
the multipotential stem cell is damaged in a way that
determines its subsequent maturation pathway. Three steps
can be defined in the evolution of some cases of pre-
leukaemia, an initial genetic change producing an abnormal
clone with a growth advantage, a second change associated
with the appearance of an abnormal karyotype, possibly in a
stem cell with a more restricted differentiation potential, and
thirdly the emergence of a leukaemic clone. If we accept that
in some cases MDS may evolve clinically from an initially
erythroid phenotype, through to a myeloid and then a more
primitive phenotype, we need to consider whether erythroid
progenitors are specifically damaged at an early stage of the
disorder, with subsequent damage occurring at other points
in the haemopoietic stem cell system or whether the entire
process can be explained by a specific sequence of stem cell
lesions determining the observed disease progression.
It is interesting that in the hierarchy of haemopoietic cells
proposed by Johnson (1981) in which stem cell maturation
involves progressive, sequential loss of differentiation
potential, the final stage in the process results in a progenitor
cell only capable of producing erythroid colonies, the
penultimate stage being bipotential for erythroid and mega-
karyocyte colonies. The clinical sequence described by
Fohlmeister et al. (1985b) almost parallels this maturation
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crythroid committed progenitor cell. Juvonen et al. (1986)
have suggested that both erythroid and megakaryocyte
colony formation are abnormal at an early stage in the
clinical development of MDS, often when CFU-GM forma-
tion remains normal, again suggesting the possibility of a
lesion in a bipotential progenitor cell. If this were so then, in
the light of Johnson's (1981) model, one might speculate that
the probability of any particular stem cell maturation stage
being a susceptible target for leukaemogenic insults may be
rclated to intrinsic physiological differences in the develop-
mcntal hierarchy such as population size, mitotic activity or
self renewal capacity. We still have no way of' dete-rmining
the number of insults or the number of targets.
It would be difficult to provide a precise model to describe
the human preleukaemic process, and it is likely that not all
cases follow the same pathway. However, our present
knowledge of the clinical syndromes is entirely consistent
with current hypotheses of the multistage development of
malignancy and oncogene function. In addition, and perhaps
more importantly, clinical preleukaemia provides us with a
definitive model of human leukaemogenesis that can be
explored in detail. We now need to characterise the earliest
abnormalities, their progression and the interrelations
between genetic lesions and functional changes in pre-
leukaemic haemopoiesis.
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